

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 1. (currently amended): A method for preventing a[[n]] viral infection in a
2 mammal, said method comprising: administering a pharmaceutically effective amount of a
3 liposomal formulation to said mammal, wherein said liposomal formulation comprises:

- 4 a) a lipid vesicle; and
5 b) ~~at least one single chain lipid active agent,~~ a fatty acid monoglyceride of
6 formula:



7
8 wherein ~~the lipid moiety of said single chain lipid active agent is required for~~
9 ~~prevention of said infection;~~ R¹ or R² is a C₂-C₁₈ alkyl group and the other is hydrogen; and,

10 wherein said viral infection is caused by an infectious agent having a lipid bilayer
11 enveloped virus.

2-5. (canceled)

1 6. (Previously presented): The method of claim 1, wherein said enveloped
2 virus is selected from the group consisting of VSV, VV, MV, HSV, and HIV.

1 7. (withdrawn): The method of claim 1, wherein said infection is a bacterial
2 infection.

1 **8.** (withdrawn): The method of claim 7, wherein said bacterial infection is
2 selected from the group consisting of Gonorrhea and Chlamydia.

1 **9.** (withdrawn): The method of claim 1, wherein said infection is a parasitic
2 protozoan infection.

1 **10.** (withdrawn): The method of claim 7, wherein said protozoa is Giardia
2 lamblia.

1 **11.** (previously presented): The method of claim 1, wherein said formulation
2 is selected from the group consisting of a topical formulation, an oral formulation, a nasal
3 formulation, an ophthalmic formulation, a rectal formulation, vaginal formulation, and parenteral
4 formulation.

1 **12.** (withdrawn): A liposomal formulation comprising:

- 2 a) a lipid vesicle; and
3 b) at least one single chain lipid active agent.

1 **13.** (withdrawn): The liposomal formulation of claim 12, wherein said active
2 agent is selected from the group consisting of a monoglyceride, a fatty acid, a lysophospholipid,
3 and a combination thereof.

1 **14.** (withdrawn): The liposomal formulation of claim 13, wherein said active
2 agent is a monoglyceride.

1 **15.** (withdrawn): The liposomal formulation of claim 14, wherein said
2 monoglyceride is a monoalkyletherglyceride with a number of carbon atoms in the alkyl moiety
3 portion being from about 2 to about 18.

1 **16.** (withdrawn): The liposomal formulation of claim 15, wherein said
2 monoglyceride is selected from the group consisting of 1 O-alkyl-sn-glycerol, 2-O-alkyl-sn-
3 glycerol, and a mixture thereof.

1 **17.** (withdrawn): The liposomal formulation of claim **16**, wherein said
2 monoglyceride is 1-O-octyl-sn-glycerol, 2-O-octyl-sn-glycerol, and a mixture thereof.

1 **18.** (withdrawn): The liposomal formulation of claim **14**, wherein said
2 monoglyceride is a single chain fatty acid monoglycerides with a number of carbon atoms in the
3 fatty acid moiety portion being from about 6 and about 12.

1 **19.** (withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle comprises a phospholipids.

1 **20.** (withdrawn): The liposomal formulation of claim **19**, wherein said
2 phospholipid is phosphatidylcholine.

1 **21.** (withdrawn): The liposomal formulation of claim **20**, wherein said lipid
2 vesicle further comprises a diluent selected from the group consisting of a co-solvent, a buffer
3 solution, an anti-oxidant, a preservative, a thickening agent and a mixture thereof.

1 **22.** (withdrawn): The liposomal formulation of claim **21**, wherein said co-
2 solvent comprises propylene glycol, ethanol, water or mixtures thereof.

1 **23.** (withdrawn): The liposomal formulation of claim **21**, wherein said anti-
2 oxidant comprises vitamin E acetate.

1 **24.** (withdrawn): The liposomal formulation of claim **21**, wherein said
2 preservative comprises methylparaben, propylparaben or mixtures thereof.

1 **25.** (withdrawn): The liposomal formulation of claim **21**, wherein said
2 thickening agent comprises Carbopol, Crothix or mixtures thereof.

1 **26.** (withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle is unilamellar.

1 **27.** (withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle is multilamellar.

1 **28.** (withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle is oligolamellar.

1 **29.** (withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle comprises a co-lipid.

1 **30.** (withdrawn): The liposomal formulation of claim **29**, wherein said co-
2 lipid is selected from the group consisting of a cholesterol, a phospholipid, a cationic lipid, an
3 anionic lipid, and a combination thereof.

1 **31.** (withdrawn): The liposomal formulation of claim **30**, wherein said
2 cationic lipid is selected from the group consisting of stearyl-amine, DC-Chol, DOTAP, and a
3 combination thereof.

1 **32.** (withdrawn): The liposomal formulation of claim **30**, wherein said
2 anionic lipid is selected from the group consisting of PS, PG, and a combination thereof.

1 **33.** (withdrawn): The liposomal formulation of claim **12**, wherein said
2 formulation is a topical formulation.

1 **34.** (withdrawn): The liposomal formulation of claim **33**, wherein said topical
2 formulation is selected from the group consisting of cream, a gel, a lotion, a suppository, a fluid
3 suspension, and a paste.

1 **35.** (withdrawn): The liposomal formulation of claim **12**, wherein said active
2 agent is encapsulated by the lipid vesicle.

1 **36.** (withdrawn): A pharmaceutical composition comprising:
2 a pharmaceutical excipient; and

3 a liposomal formulation comprising a lipid vesicle and at least one single chain
4 lipid active agent.

1 **37.** (withdrawn): The composition of claim **36**, wherein said excipient
2 comprises an antioxidant, a co-solvent, a preservative, a flavoring agent, vitamin, a thickening
3 agent, a buffer solution, a wetting agent, an emulsifying agent, a suspending agent, a sweetening
4 agent, a flavoring agent, a perfuming agent or mixtures thereof.

1 **38.** (new): The method of claim **1**, wherein said C₂-C₁₈ alkyl group is a C₆-
2 C₁₂ alkyl group.

1 **39.** (new): The method of claim **38**, wherein said fatty acid monoglyceride is
2 1-O-octyl-sn-glycerol or 2-O-octyl-sn-glycerol.

1 **40.** (new): The method of claim **39**, wherein said enveloped virus is selected
2 from the group consisting of VSV, VV, MV, HSV, and HIV.

1 **41.** (new): The method of claim **40**, wherein said formulation is selected from
2 the group consisting of a topical formulation, an oral formulation, a nasal formulation, an
3 ophthalmic formulation, a rectal formulation, vaginal formulation, and parenteral formulation.
4